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Abstract 
Background: Poor glycemic control in patients with type 2 diabetes is commonly recorded worldwide; Latin Amer-
ica (LA) is not an exception. Barriers to intensifying insulin therapy and which barriers are most likely to negatively 
impact outcomes are not completely known. The objective was to identify barriers to insulin progression in individu-
als with type 2 diabetes mellitus (T2DM) in LA countries (Mexico, Brazil, and Argentina).
Methods: MOSAIc is a multinational, non-interventional, prospective, observational study aiming to identify the 
patient-, physician-, and healthcare-based factors affecting insulin intensification. Eligible patients were ≥18 years, 
had T2DM, and were treated with insulin for ≥3 months with/without oral antidiabetic drugs (OADs). Demographic, 
clinical, and psychosocial data were collected at baseline and regular intervals during the 24-month follow-up period. 
This paper however, focuses on baseline data analysis. The association between glycated hemoglobin (HbA1c) and 
selected covariates was assessed.
Results: A trend toward a higher level of HbA1c was observed in the LA versus non-LA population (8.40 ± 2.79 
versus 8.18 ± 2.28; p ≤ 0.069). Significant differences were observed in clinical parameters, treatment patterns, and 
patient-reported outcomes in LA compared with the rest of the cohorts and between Mexico, Brazil, and Argentina. 
Higher number of insulin injections and lower number of OADs were used, whereas a lower level of knowledge and 
a higher level of diabetes-related distress were reported in LA. Covariates associated with HbA1c levels included age 
(−0.0129; p < 0.0001), number of OADs (0.0835; p = 0.0264), higher education level (−0.2261; p = 0.0101), healthy 
diet (−0.0555; p = 0.0083), self-monitoring blood glucose (−0.0512; p = 0.0033), hurried communication style in 
the process of care (0.1295; p = 0.0208), number of insulin injections (0.1616; p = 0.0088), adherence (−0.1939; 
p ≤ 0.0104), and not filling insulin prescription due to associated cost (0.2651; p = 0.0198).
Conclusion: MOSAIc baseline data showed that insulin intensification in LA is not optimal and identified several 
conditions that significantly affect attaining appropriate HbA1c values. Tailored public health strategies, including 
education, should be developed to overcome such barriers.
Trial Registration NCT01400971
Keywords: Type 2 diabetes, Latin America, Observational study, Quality of care, Psychological impact, Diabetes 
knowledge, Diabetes self-care management, Insulin treatment, Diabetes education
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/




*Correspondence:  linetzky_bruno@lilly.com 
1 Eli Lilly and Company, Tronador 4890, Piso 12, CABA,  
C1430DNN Buenos Aires, Argentina
Full list of author information is available at the end of the article
Page 2 of 10Linetzky et al. Diabetol Metab Syndr  (2016) 8:41 
Background
Although it is widely accepted that tight glycemic con-
trol is associated with a decreased risk of diabetes-related 
complications [1–5], poor control (herein defined as 
HbA1c >7.0  %) is commonly recorded worldwide and 
the available data show that Latin America (LA) is not 
an exception [6–11]. Despite clear treatment algorithms 
established within international guidelines, insulin ther-
apy is frequently delayed even after long periods of poor 
metabolic control [12, 13]. Furthermore, observational 
data and evidence provided by multiple clinical trials 
implemented in different countries demonstrate a lack 
of treatment goal achievement among insulin-treated 
patients [14–18].
Although insulin therapy has been shown to sig-
nificantly reduce glycated hemoglobin (HbA1c) levels, 
patients and physicians are often reluctant to initiate 
insulin therapy. Studies suggest that the reasons for this 
inertia on behalf of patients include a perceived lack of 
efficacy, negative impact on lifestyle, injection phobia, 
and fear of weight gain or hypoglycemic events [19]. 
Physician barriers include fears for their patients’ safety 
(including weight gain and hypoglycemia), a perceived 
greater drain on physician’s resources (time and cost), 
and concern that insulin regimens are too complex for 
patients to understand and will result in poor adherence 
[20]. Health care system factors, such as limited access to 
medication, care, and out of pocket expenditures, repre-
sent additional barriers to insulin therapy initiation [21–
23]. This multicomponent situation represents the major 
hurdles to overcome to achieve a successful initiation of, 
and persistence on, insulin therapy.
Despite these known barriers and their negative impact 
on the achievement of appropriate metabolic control, 
to the authors’ knowledge no longitudinal study is cur-
rently available that attempts to address this important 
issue. Moreover, considering the scarce achievement of 
treatment goals in patients under insulin treatment, it is 
necessary to identify the barriers to intensifying insulin 
therapy and which of these barriers are most likely to 
impact outcomes.
The Multinational Observational Study Assessing Insu-
lin use (MOSAIc) study is a multinational observational 
cohort study aiming at identifying the patient-, physi-
cian-, and health care environment-based factors asso-
ciated with insulin initiation and progression in patients 
with type 2 diabetes mellitus (T2DM) in real-world prac-
tice. Data collected include demographic, clinical, and 
psychosocial indicators at the patient and physician level 
and practice site characteristics recorded at baseline and 
regular intervals during a 24-month follow-up period 
[24]. This analysis attempts to identify particular chal-
lenges faced by patients treated with insulin in LA. We 
have compared baseline demographic, clinical, and psy-
chosocial characteristics of the overall MOSAIc cohort to 
that of three LA countries.
Methods
Study design
The rationale and design of the MOSAIc study have been 
reported elsewhere [24]. Briefly, MOSAIc is a multina-
tional, non-interventional, prospective, observational 
cohort study due for completion in December 2015. Par-
ticipants were recruited from July 2011 to July 2013 at 
223 sites in 18 countries [United Arab Emirates (UAE), 
Argentina, Brazil, Canada, China, Germany, India, Israel, 
Italy, Japan, Mexico, Russia, Saudi Arabia, South Korea, 
Spain, Turkey, the UK, and the US (including Puerto 
Rico)].
Study sites represented a combination of specialist 
and general practice centers in urban and rural areas. 
Participants were followed for 2 years after study enroll-
ment, with visit windows approximately 6, 12, 18, and 
24 months after the baseline visit, with such visits being 
part of their usual care.
The study was conducted following the ethical prin-
ciples of the Helsinki Declaration, in accordance with 
good clinical practices and the applicable laws and regu-
lations of the participant countries. The MOSAIc study 
was registered under ClinTrials.gov (NCT01400971). All 
patients completed informed consent forms approved by 
their country-specific institutional review boards (can be 
provided on request). The study’s analytic plan has been 
approved by the Brigham and Women’s Hospital Institu-
tional Review Board.
Study population
Inclusion criteria for participation in MOSAIc were 
age ≥18  years; diagnosis of T2DM; presentation to a 
study site as part of usual medical care; use of any com-
mercially available initial insulin therapy for at least 
3 months with or without any combination of approved 
non-insulin oral antidiabetic drugs (OADs) (e.g., met-
formin); and sufficient understanding of the primary 
language of the country to complete study surveys. 
Exclusion criteria were participation in another medi-
cal research study; use of intensive basal-bolus therapy 
(basal insulin in addition to three prandial doses); or ini-
tiation of insulin treatment with three daily injections of 
mixed insulin.
Baseline data collection and patient‑reported outcomes
Patient data for demographic and clinical characteristics, 
comorbid conditions, and insulin regimen were retro-
spectively collected (limited to 6 months before the base-
line visit) from medical records at the study site.
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Extensive information on patient-reported diabetes- 
and insulin-related knowledge, attitudes, hypoglycemia, 
general health behaviors, patient-provider relationship, 
and perceived physical and psychological well-being were 
collected at baseline using self-report questionnaires.
The Brief Diabetes Knowledge Test was used to evalu-
ate patients’ understanding of their disease, such as how 
to manage insulin administration and how to treat hypo-
glycemia, with a summary score ranging from 0 (no ques-
tions correct) to 9 (all correct) [25].
The 17-item Diabetes Distress Scale was used to meas-
ure patients’ degree of concern about different aspects of 
their type 2 diabetes care and treatment, using a six-point 
Likert scale ranging from “Not a problem” to “A very seri-
ous problem” [26]. Mean items score and standard devia-
tion (SD) are reported.
The Insulin Specific Adherence Questionnaire was used 
to evaluate adherence to insulin therapy and included a 
question to assess patients’ willingness to increase the 
frequency of injections. This question asked the partici-
pant to indicate to what extent he/she agreed with the 
statement: “I am willing to add additional injections to 
control my diabetes”.
The 25-item Interpersonal Processes of Care (IPC) 
survey measured how patients’ perceived the quality 
of their relationship with their providers over the past 
12 months. Five alternative responses were provided for 
each question: 1 (never), 2 (rarely), 3 (sometimes), 4 (usu-
ally), and 5 (always). There are four positive IPC domains 
(elicited concerns, explained results, patient-centered 
decisions, and compassionate/respectful) in which higher 
scores correspond to better perceived interactions. Two 
IPC domains (hurried communication and discrimina-
tion) that were negatively framed in a way that better per-
ceived interactions are represented by a lower score [27].
The Summary of Diabetes Self-Care Activities ques-
tionnaire was also administered in the study, analyzing 
three questions: “On how many of the last 7 days did you 
test your blood sugar the number of times recommended 
by your health-care provider?”, “How many of the last 
7  days have you followed a healthful eating plan?”, and 
“On how many of the last 7 days did you participate in at 
least 30 min of physical activity?”. Responses ranged from 
0 to 7 [28].
Statistical analysis
Baseline participant characteristics were analyzed by 
region comparing LA participants with the rest of the 
cohort and by country comparing participants from 
Argentina, Brazil, and Mexico.
Categorical variables were described as the number and 
percentage of participants, and continuous variables were 
described using the mean and SD. Multiple imputation 
by Chained Equation was used to impute missing items 
[29]. Pooled analysis of variance (ANOVA) was used for 
continuous variables when comparing regional differ-
ences depending on whether the variables were imputed. 
Comparison of categorical variables was primarily 
undertaken using the Chi square test, except for insu-
lin regimen where the Fisher’s exact test was used. The 
Cochran–Mantel–Haenszel test was used when compar-
ing the number of oral agents. Pooled multivariate linear 
regression models were used to assess the association 
between HbA1c and selected covariates. For all statisti-
cal analyses, the significance level was set at ≤0.05. The 
imputation was done using Stata 13 (StataCorp LP; Col-
lege Station, TX). All other analyses used SAS version 9.2 
software (SAS Institute; Cary, NC).
Results
A total of 4341 patients met all MOSAIc eligibility 
criteria and comprised the analyzed population; 521 
were from LA (Argentina  =  160; Brazil  =  155; Mex-
ico = 206). Demographic, clinical, and metabolic char-
acteristics are listed in Table  1. Data were grouped as 
LA and non-LA participants, as well as by the three 
different LA countries. Comparable age values were 
recorded in all groups. Patients from Argentina were 
significantly older than those from the other two LA 
countries (p ≤ 0.0001).
The LA region had a higher percentage of female par-
ticipants (56.2  %) compared to the global population, 
particularly in Brazil (64.5  %). Similarly, a significantly 
higher rate of participants with an education level of pri-
mary school or lower was also recorded in LA compared 
to non-LA countries (48.2 versus 27.2 %), particularly in 
Argentina (51.9 %) and Brazil (50.0 %). There was also a 
significant difference comparing the percentage of people 
with health insurance, with the lowest figures recorded in 
Mexico (25.2 %). The LA population had a longer dura-
tion of diabetes than the overall MOSAIc cohort, with 
no significant difference among the three LA countries. 
Conversely, the rate of comorbidities (associated cardio-
vascular risk factors, microvascular complications, and 
macrovascular events) was lower in the LA population.
Baseline HbA1c levels were above the treatment tar-
gets recommended by international guidelines, with no 
significant differences among all the groups, although 
lower levels were recorded in the non-LA population 
(8.40 ± 2.79 versus 8.18 ± 2.28; p ≤ 0.069). Among LA 
countries, higher but not significantly different HbA1c 
values were recorded in Mexico (8.70 ± 3.55).
There were no significant differences between par-
ticipants classified as overweight from LA or non-LA 
countries; conversely, there were significant differences 
among those classified as obese among countries, with 
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the highest and lowest rates recorded in Argentina and 
Mexico, respectively (p ≤ 0.0001).
Systolic blood pressure values were close to target 
values recommended by international guidelines, with 
Brazil and Mexico having the highest and lowest values, 
respectively (p = 0.0214).
Treatment patterns varied across countries included in 
the study (Table 2). A higher number of daily insulin injec-
tions were reported in LA compared to non-LA countries, 
with Argentina having significantly more reported insu-
lin injections compared to Brazil and Mexico (p ≤ 0.0001 
for both). Basal insulin alone was more frequently used in 
LA than in the rest of the MOSAIc cohort, with the high-
est rate recorded in Brazil among LA countries (74.8  %; 
p ≤ 0.0001). A higher percentage of LA participants also 
required basal insulin more than once per day. Important 
differences were also recorded in the use of concomitant 
OADs agents between the LA and non-LA population, 
as well as within LA countries (p  ≤  0.0001 for both). 
Metformin was the most commonly utilized therapy, 
with the highest and lowest figures recorded in Brazil and 
Mexico, respectively (p ≤ 0.0001).
Individual Diabetes Knowledge scores were low in the 
overall MOSAIc population, with lower figures in the LA 
versus non-LA countries (4.16 ± 2.23 versus 4.89 ± 2.19; 
p  <  0.0001). The lowest figures were recorded in Mex-
ico (3.93 ±  2.10) and Brazil (3.88 ±  1.91) (p =  0.0002) 
(Table 3).
A small but statistically significant difference was 
observed in the patients’ Diabetes Distress Scale scores 
between LA and the rest of the study population 
(p ≤ 0.0001); an important and significant difference was 
also observed among LA countries, with highest level of 
distress recorded in Brazil (3.14 ± 1.36) and the lowest in 
Argentina (2.17 ± 1.19) (p ≤ 0.0001) (Table 3).
The summary of self-care activities questionnaire 
showed a lower number of days with at least 30  min of 
physical activity reported among study participants 
Table 1 Demographic, clinical, and metabolic characteristics of the population by region and country
BMI body mass index, CAD coronary artery disease, LA = Latin America, MI myocardial infarction, SD standard deviation
All Mosaic  
cohort
LA Non‑LA  
countries
p Argentina Brazil México p
Mean age, years (SD) 61.77 (11.02) 61.99 (11.21) 61.74 (10.99) 0.6326 65.48 (10.55) 61.03 (9.51) 60.00 (12.26) <0.0001
Gender—females, n (%) 2176 (50.1 %) 293 (56.2 %) 1883 (49.3 %) 0.0029 76 (47.5 %) 100 (64.5 %) 117 (56.8 %) 0.0095
Education
 Primary school, n (%) 1291 (29.7 %) 251 (48.2 %) 1040 (27.2 %) <0.0001 83 (51.9 %) 65 (41.9 %) 103 (50.0 %) 0.0474
 High school or more, 
n (%)
2715 (62.5 %) 235 (45.1 %) 2480 (64.9 %) 69 (43.1 %) 69 (44.5 %) 97 (47.1 %)
Insurance
 Private, n (%) 917 (21.1 %) 134 (25.7 %) 783 (20.5 %) 0.0223 56 (35.0 %) 48 (31.0 %) 30 (14.6 %) <0.0001
 Public, n (%) 2229 (51.3 %) 247 (47.4 %) 1982 (51.9 %) 65 (40.6 %) 76 (49.0 %) 106 (51.5 %)
 Uninsured, n (%) 848 (19.5 %) 103 (19.8 %) 745 (19.5 %) 35 (21.9 %) 16 (10.3 %) 52 (25.2 %)
Mean diabetes dura-
tion, years (SD)
12.65 (7.98) 13.52 (8.77) 12.54 (7.87) 0.0083 13.71 (9.77) 13.46 (7.78) 13.42 (8.69) 0.9492
Comorbidities
 MI or CAD, n (%) 824 (19.0 %) 38 (7.3 %) 786 (20.6 %) <0.0001 16 (10.0 %) 15 (9.7 %) 7 (3.4 %) 0.0217
 Stroke, n (%) 151 (3.5 %) 10 (1.9 %) 141 (3.7 %) 0.0384 4 (2.5 %) 5 (3.2 %) 1 (0.5 %) 0.1393
 Congestive heart 
failure, n (%)
237 (5.5 %) 6 (1.2 %) 231 (6.0 %) <0.0001 0 (0.0 %) 3 (1.9 %) 3 (1.5 %) 0.2383
 Nephropathy, n (%) 685 (15.8 %) 48 (9.2 %) 637 (16.7 %) <0.0001 14 (8.8 %) 17 (11.0 %) 17 (8.3 %) 0.6574
 Neuropathy, n (%) 1194 (27.5 %) 85 (16.3 %) 1109 (29.0 %) <0.0001 14 (8.8 %) 22 (14.2 %) 49 (23.8 %) 0.0004
 Retinopathy, n (%) 954 (22.0 %) 78 (15.0 %) 876 (22.9 %) <0.0001 24 (15.0 %) 24 (15.5 %) 30 (14.6 %) 0.9709
 Depression, n (%) 370 (8.5 %) 46 (8.8 %) 324 (8.5 %) 0.7899 4 (2.5 %) 16 (10.3 %) 26 (12.6 %) 0.0024
Hypertension, n (%) 2994 (69.0 %) 335 (64.3 %) 2659 (69.6 %) 0.0140 112 (70.0 %) 110 (71.0 %) 113 (54.9 %) 0.0013
Hyperlipidemia, n (%) 2484 (57.2 %) 259 (49.7 %) 2225 (58.2 %) 0.0002 81 (50.6 %) 93 (60.0 %) 85 (41.3 %) 0.0019
HbA1c, mean (SD) 8.20 (2.47) 8.40 (2.79) 8.18 (2.28) 0.0686 8.08 (2.05) 8.34 (2.38) 8.70 (3.55) 0.1108
HbA1c physician 
reported goal (SD)
7.02 (0.77) 7.10 (0.76) 7.01 (0.73) 0.011 7.17 (0.65) 7.11 (0.89) 7.04 (0.79) 0.2917
BMI, mean (SD) 29.58 (6.39) 29.78 (5.64) 29.55 (6.49) 0.4437 31.24 (6.22) 30.21 (5.46) 28.32 (4.81) <0.0001
Systolic blood pressure, 
mean (SD)
132.42 (16.83) 132.94 (17.24) 132.34 (16.72) 0.4395 133.64 (13.69) 135.49 (19.88) 130.49 (17.54) 0.0214
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in LA. Comparison of the number of days performing 
self-monitoring activities among the three LA coun-
tries showed higher values in Argentina, higher number 
of days following a healthy diet in Argentina and Brazil, 
and more days with physical activity practices in Mexico 
(Table 3).
A similar level of adherence was reported in LA com-
pared to the rest of the MOSAIc participants, but a trend 
to a lower level of adherence was reported in Brazil 
(67.1 %). LA patients expressed more willingness to add 
additional injections to control their diabetes (67.4 versus 
53.2 %; p < 0.0001).
Although no significant difference in the rate of not fill-
ing the prescription due to cost was observed between 
LA and the rest of the MOSAIc cohort, important varia-
tions were observed at the country level, with the lowest 
and highest rates in Argentina and Mexico, respectively 
(p = 0.0004).
Differences in the nature of the reported patient-
health care provider relationship are depicted in Table 3. 
Lower levels of “hurried communication” were reported 
in Argentina, as well as higher scores in the domains of 
“elicited concerns”, “explained results”, “compassionate 
and respectful style”, and “patient centered decision mak-
ing”, compared to the other LA countries.
Table 4 shows the analysis of variables associated with 
HbA1c levels. After the adjustment for potential con-
founders, patients in LA countries had similar levels 
of HbA1c compared to the rest of the MOSAIc cohort. 
The variables significantly associated with HbA1c lev-
els were age (−0.0129; p  <  0.0001), number of other 
OADs (0.0835; p  =  0.0264), having higher education 
level (−0.2261; p  =  0.0101), following a healthy diet 
(−0.0555; p  =  0.0083), self-monitoring blood glucose 
(−0.0512; p = 0.0033), a hurried communication style in 
the interpersonal process of care questionnaire (0.1295; 
Table 2 Treatment patterns by region and country
GLP1 Glucagon-like peptide-1, LA Latin America, OADs oral antidiabetic drugs, SD standard deviation
All Mosaic 
cohort
LA Non‑LA  
countries
p Argentina Brazil México p
Freq of insulin injections/
day mean
1.63 (0.68) 1.80 (0.68) 1.60 (0.67) <0.0001 1.99 (0.76) 1.73 (0.73) 1.69 (0.54) <0.0001
Insulin regimen
 Basal insulin only
  Overall, n (%) 2168 (49.9 %) 365 (70.1 %) 1803 (47.2 %) <0.0001 103 (64.4 %) 116 (74.8 %) 146 (70.9 %) <0.0001
  Once, n (%) 1656 (76.4 %) 152 (41.6 %) 1504 (83.4 %) 37 (35.9 %) 52 (44.8 %) 63 (43.2 %)
  More than once, n (%) 512 (23.6 %) 213 (58.4 %) 299 (16.6 %) 66 (64.1 %) 64 (55.2 %) 83 (56.8 %)
 Mixed insulin only
  Overall, n (%) 1284 (29.6 %) 70 (13.4 %) 1214 (31.8 %) 36 (22.5 %) 0 (0.0 %) 34 (16.5 %)
  Once, n (%) 112 (8.7 %) 4 (5.7 %) 108 (8.9 %) 1 (2.8 %) 0 (0.0 %) 3 (8.8 %)
  More than once, n (%) 1172 (91.3 %) 66 (94.3 %) 1106 (91.1 %) 35 (97.2 %) 0 (0.0 %) 31 (91.2 %)
 Short acting only
  Overall, n (%) 170 (3.9 %) 11 (2.1 %) 159 (4.2 %) 1 (0.6 %) 1 (0.6 %) 9 (4.4 %)
  Once, n (%) 37 (21.8 %) 2 (18.2 %) 35 (22.0 %) 1 (100.0 %) 0 (0.0 %) 1 (11.1 %)
  More than once, n (%) 133 (78.2 %) 9 (81.8 %) 124 (78.0 %) 0 (0.0 %) 1 (100.0 %) 8 (88.9 %)
 Other insulin combinations
  Overall, n (%) 597 (13.8 %) 64 (12.3 %) 533 (14.0 %) 20 (12.5 %) 27 (17.4 %) 17 (8.3 %)
  Once, n (%) 172 (28.8 %) 14 (21.9 %) 158 (29.6 %) 2 (10.0 %) 9 (33.3 %) 3 (17.6 %)
  More than once, n (%) 425 (71.2 %) 50 (78.1 %) 375 (70.4) 18 (90.0 %) 18 (66.7 %) 14 (82.4 %)
Other antidiabetic medication
 No. of OADs, mean (SD) 1.22 (1.09) 0.84 (0.88) 1.27 (1.10) <0.0001 0.66 (0.68) 1.33 (0.91) 0.61 (0.84) <0.0001
 Metformin, n (%) 2437 (56.1 %) 280 (53.7 %) 2157 (56.5 %) 0.2400 82 (51.3 %) 122 (78.7 %) 76 (36.9 %) <0.0001
 Sulfonylurea, n (%) 1389 (32.0 %) 92 (17.7 %) 1297 (34.0 %) <0.0001 13 (8.1 %) 55 (35.5 %) 24 (11.7 %) <0.0001
 Dipeptidyl peptidase-4 
inhibitor, n (%)
538 (12.4 %) 38 (7.3 %) 500 (13.1 %) 0.0002 2 (1.3 %) 20 (12.9 %) 16 (7.8 %) 0.0003
 Alpha-glucosidase inhibi-
tor, n (%)
321 (7.4 %) 7 (1.3 %) 314 (8.2 %) <0.0001 1 (0.6 %) 2 (1.3 %) 4 (1.9 %) 0.5536
 GLP-1, n (%) 143 (3.3 %) 5 (1.0 %) 138 (3.6 %) 0.0015 2 (1.3 %) 2 (1.3 %) 1 (0.5 %) 0.6678
 Other drug, n (%) 443 (10.2 %) 14 (2.7 %) 429 (11.2 %) <0.0001 5 (3.1 %) 5 (3.2 %) 4 (1.9 %) 0.6952
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p  =  0.0208), the number of insulin injections (0.1616; 
p  =  0.0088), being adherent to the insulin treatment 
(−0.1939; p = 0.0104), and no insulin prescription adher-
ence due to associated cost (0.2651; p = 0.0198).
Discussion
The current analysis of MOSAIc study baseline data 
provides relevant information regarding the potential 
challenges that individuals with T2DM face when using 
insulin in LA countries. Although people from the three 
LA countries included in the study share some of these 
challenges with the whole cohort, others appear to be 
more specific for the region. These findings highlight, 
from a public health perspective, the importance of 
implementing more locally tailored solutions to optimize 
blood glucose control in individuals with T2DM treated 
with insulin.
A common problem recorded was the poor degree of 
metabolic control (HbA1c  ≈  8  %), that coincides with 
data reported consistently in previous studies [7, 9, 10, 
30].
This poor metabolic control was observed despite the 
wide variety of treatment patterns recorded in the stud-
ied population; in fact, patients in the three LA countries 
have a different treatment pattern compared to other 
regions, namely, a higher rate of basal insulin use and a 
lower rate of OADs agents used. Conversely, a compara-
ble rate of metformin prescription was recorded in LA 
and non-LA countries. However, metformin was differ-
ently prescribed in LA countries, with a higher rate in 
Brazil (78.7  %) and a lower rate in Mexico (37  %). The 
recommendation of Asociación Latinoamericana de Dia-
betes (ALAD) guidelines regarding the use of metformin 
and precaution with the use of sulfonylureas may explain, 
at least partly, such a prescription pattern [31].
The low rate of incretin therapies use is also notewor-
thy, despite data showing that they are associated with a 
better HbA1c control and a lower risk of hypoglycemia 
and weight gain compared to insulin treated patients 
[32–34]. Clearly, none of the variety of treatment alter-
natives employed were effective in attaining the HbA1c 
target values recommended by international guidelines 
to prevent development and progression of chronic 
complications.
The linear regression analysis identified many variables 
associated with attainment of HbA1c treatment goals, 
with some of them unmodifiable (such as the age of the 
patients). Similar results have been reported in the ABCs 
of good management study in China [35, 36].
Other variables identified were the number of other 
associated OADs, the number of insulin injections, and 
adherence to insulin treatment, demonstrating once 
Table 3 Self-reported outcomes by region and country
DDS Diabetes Distress Scale, IPC Interpersonal Processes of Care, LA Latin America
All Mosaic 
cohort
LA Non‑LA  
countries
p Argentina Brazil México p
Diabetes knowledge, mean (SD) 4.80 (2.26) 4.16 (2.23) 4.89 (2.19) <0.0001 4.72 (2.30) 3.88 (1.91) 3.93 (2.10) 0.0002
DDS total, mean (SD) 2.27 (1.14) 2.49 (1.32) 2.24 (1.11) <0.0001 2.17 (1.19) 3.14 (1.36) 2.26 (1.21) <0.0001
Self-care activities
 Self-monitoring, mean (SD) 3.60 (2.62) 3.70 (2.68) 3.58 (2.64) 0.3238 4.89 (2.52) 3.30 (2.64) 3.09 (2.52) <0.0001
 General diet, mean (SD) 4.44 (2.24) 4.57 (2.21) 4.42 (2.24 0.1576 4.86 (2.02) 3.89 (2.49) 4.85 (2.11) <0.0001
 Exercise mean (SD) 2.86 (2.44) 2.42 (2.40) 2.92 (2.43) <0.0001 2.14 (2.32) 1.93 (2.35) 3.01 (2.37) <0.0001
Adherence (does not miss shots), 
n (%)
3290 (75.8 %) 398 (76.4 %) 2892 (75.7 %) 0.7793 134 (83.8 %) 104 (67.1 %) 160 (77.7 %) 0.0622
Willingness to add additional 
injection, n (%)
2383 (54.9 %) 351 (67.4 %) 2032 (53.2 %) <0.0001 99 (61.9 %) 107 (69.0 %) 145 (70.4 %) 0.1973
Not fill in insulin prescription due 
to cost, n (%)
460 (10.6 %) 53 (10.2 %) 407 (10.7 %) 0.5832 6 (3.8 %) 14 (9.0 %) 33 (16.0 %) 0.0004
IPC
 Hurried communication, mean 
(SD)
1.57 (0.70) 1.53 (0.77) 1.58 (0.69) 0.1184 1.25 (0.42) 1.69 (0.80) 1.62 (0.88) <0.0001
 Elicited concerns, mean (SD) 3.92 (1.05) 3.73 (1.18) 3.95 (1.03) <0.0001 4.15 (0.91) 3.51 (1.17) 3.56 (1.25) <0.0001
 Explained results-medications, 
mean (SD)
3.92 (1.02) 4.03 (1.04) 3.91 (1.01) 0.0110 4.41 (0.68) 3.84 (1.07) 3.87 (1.17) <0.0001
 Patient-centered decision mak-
ing, mean (SD)
3.37 (1.22) 3.30 (1.35) 3.37 (1.20) 0.2293 3.74 (1.15) 2.87 (1.20) 3.29 (1.47) <0.0001
 Compassionate, respectful, 
mean (SD)
4.10 (0.89) 4.16 (0.97) 4.10 (0.87) 0.1189 4.53 (0.61) 4.12 (0.99) 3.90 (1.11) <0.0001
 Discriminated, mean (SD) 1.50 (0.73) 1.43 (0.67) 1.51 (0.73) 0.0123 1.45 (0.69) 1.37 (0.68) 1.46 (0.66) 0.4117
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again that adherence is a key factor in attaining treatment 
targets whereas treatment complexity negatively affects 
long-term adherence and increases hospitalization rates 
[37]. The cost of treatment was also identified as a poten-
tial barrier to attaining Hb1c target values, which was 
confirmed by several other studies [23, 38].
Other factors affecting the attainment of HbA1c target 
values included level of education, healthy diet, perfor-
mance of self-monitoring blood glucose, and a hurried 
communication style in the interpersonal process of 
care. Certainly, all of them have a common denominator: 
education.
Several authors have shown, in many populations, that 
educational programs using cognitive reframing are asso-
ciated with improved outcomes [39–41]. Furthermore, 
Brownson et  al. also reported that self-management 
programs for T2DM implemented at the primary care 
level were cost-effective from the perspective of a health-
care system when considering cost savings as a result of 
reductions in long-term complications [42].
In LA, we have shown that the implementation of 
a structured education program for individuals with 
T2DM (PEDNID-LA, Programa de Educación de Diabé-
ticos No Insulinodependientes en América Latina) signif-
icantly improved the clinical and metabolic parameters 
that were tested and decreased the cost of treatment by 
64  % [39]. More recently, the 3-year prospective educa-
tion study implemented in the province of Corrientes 
(Argentina; PRODIACOR, PROgrama DIAbetes COR-
rientes), demonstrated similar clinical, metabolic, and 
psychological improvements [43]. This study also showed 
that education, regardless of the method used, is an effec-
tive tool to improve the care and outcomes of those with 
T2DM. However, the combined education of patients 
and physicians provided the greatest and most consistent 
and sustained clinical and metabolic improvement at the 
best drug treatment cost-effective ratio [43].
Similarly, a long-term multi-center education trial 
implemented in Italy by Trento and colleagues showed 
that healthcare behaviors, clinical and metabolic 
Table 4 Variables associated with HBA1c levels (univariate and multivariate analysis)
BMI body mass index, CI confidence interval, DDS Diabetes Distress Scale, IPC Interpersonal Process of Care, LA Latin America, OADs oral antidiabetic drugs, SC self-care
Unadjusted regression Adjusted regression
Estimate 95 % CI p Estimate 95 % CI p value
Age −0.0206 (−0.03, −0.02) <0.0001 −0.0129 (−0.02, −0.01) 0.0001
Gender—female 0.1085 (−0.01, 0.23) 0.0735 0.0589 (−0.07, 0.19) 0.3632
Diabetes duration −0.0054 (−0.01, 0.00) 0.1866 0.0036 (−0.01, 0.01) 0.4219
BMI 0.0114 (−0.00, 0.02) 0.0643 0.0075 (−0.00, 0.02) 0.2243
Number of OAD 0.0631 (−0.00, 0.13) 0.0639 0.0835 (0.01, 0.16) 0.0264
Insulin-mixed only 0.1715 (0.03, 0.31) 0.0143 0.0402 (−0.14, 0.22) 0.6625
 Short acting only 0.4457 (0.11, 0.78) 0.0098 0.3583 (−0.00, 0.72) 0.0506
 Other 0.2045 (0.02, 0.39) 0.0323 0.0892 (−0.11, 0.29) 0.3717
Country group—LA 0.2248 (−0.01, 0.46) 0.0620 0.2129 (−0.05, 0.48) 0.1077
Education level—high school −0.1189 (−0.28, 0.04) 0.1496 −0.1436 (−0.32, 0.03) 0.1010
 College −0.1936 (−0.36, −0.03) 0.0211 −0.2261 (−0.40, −0.06) 0.0101
Insurance status—public −0.2764 (−0.46, −0.09) 0.0037 −0.1834 (−0.38, 0.02) 0.0700
 Private −0.2186 (−0.48, 0.04) 0.0974 −0.1407 (−0.40, 0.12) 0.2788
SC—general diet −0.0758 (−0.12, −0.04) 0.0004 −0.0555 (−0.10, −0.02) 0.0083
 Specific diet −0.0329 (−0.08, 0.01) 0.1451 −0.0368 (−0.08, 0.01) 0.1025
 Exercise −0.0413 (−0.07, −0.01) 0.0035 −0.0266 (−0.06, 0.00) 0.0798
 Blood Glucose testing −0.0658 (−0.09, −0.04) <0.0001 −0.0512 (−0.08, −0.02) 0.0033
IPC-hurried communication 0.1800 (0.08, 0.28) 0.0004 0.1295 (0.02, 0.24) 0.0208
 Elicited concerns 0.0145 (−0.08, 0.11) 0.7506 0.0414 (−0.05, 0.13) 0.3745
 Explained results −0.0424 (−0.15, 0.06) 0.4186 −0.0038 (−0.11, 0.10) 0.9422
 Patient-centered decision 0.0251 (−0.06, 0.11) 0.5659 0.0513 (−0.03, 0.14) 0.2323
 Compassionate/respectful −0.0346 (−0.14, 0.07) 0.5215 −0.0109 (−0.12, 0.10) 0.8461
 Discriminated style −0.0039 (−0.11, 0.11) 0.9434 −0.0818 (−0.19, 0.03) 0.1403
DDS-total distress 0.1682 (0.11, 0.23) <0.0001 0.0660 (−0.00, 0.14) 0.0655
Insulin injection frequency 0.2001 (0.10, 0.30) 0.0002 0.1616 (0.04, 0.28) 0.0088
Adherence (no missed shots) −0.4575 (−0.60, −0.32) <0.0001 −0.1939 (−0.34, −0.05) 0.0104
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indicators, and quality of life were significantly better in 
the intervention group than in the control group [44].
Our study has several limitations, mainly associated 
with the nature of observational research (i.e., observa-
tional studies cannot provide causal evidence of an effect, 
in our case the real impact of conditioning factors on 
attainment of HbA1c target values). Baseline data were 
not available for all patients for all variables considered, 
thus we used multiple imputation with chained equa-
tions, a well-recognized method that accommodates both 
categorical and continuous variables, to impute missing 
values. Although this approach assumes that the missing 
values are missed at random, it is not possible to prove 
this assumption. Consequently, we also used a complete 
case analysis approach and results were quantitatively 
similar. Finally, the demographic, clinical, and psycho-
social characteristics of the enrolled patients may be dif-
ferent from those individuals with T2DM in the general 
population of each country (24); this last bias could be of 
a lower magnitude because we recruited patients from 
both endocrinology and primary care practice sites with 
different practice locations (urban/rural), sizes, and prac-
tice types (academic/stand-alone) to maximize the data 
generalizability.
Conclusions
The MOSAIc baseline data showed that patients under 
an initial scheme of insulin treatment in LA and non-
LA countries are not achieving appropriate glycemic 
control, and  this analysis identified several conditions 
that significantly affect the attainment of HbA1c val-
ues suggested by international guidelines. Appropriate 
glycemic control can effectively prevent the develop-
ment and progression of chronic complications that 
decrease quality of life and increase cost of care over 
time. Although some of these factors are not modifiable 
(e.g., age), most of them can be significantly removed 
by educational strategies. Therefore, policy makers, 
particularly in the LA region where health resources 
are frequently scarce, might seriously consider the wide 
implementation of educational activities to improve 
the metabolic control of individuals with diabetes. This 
strategy could effectively decrease the heavy burden of 
the disease on health budget, the society, and particu-
larly on individuals with diabetes.
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